If you're having trouble finding what you're looking for in the MEP and you're a member of the RPS, please contact our Support Team via email at [email protected] or by phone on 0333 733 2570 with what you're looking for.
Advances in biotechnology have resulted in an increasing number of biological molecules and materials being used as medicines. This is a trend that is expected to continue, at least for the foreseeable future. A number of patents and periods of marketing exclusivity for biological medicines are expiring and biosimilar versions of the medicines are becoming more widely available e.g. insulin glargine. The introduction of biosimilars offers potential benefits in terms